EEG evidence of compensatory mechanisms in preclinical Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
Early biomarkers are needed to identify individuals at high risk of preclinical Alzheimer’s disease and to better understand the pathophysiological processes of disease progression. Preclinical Alzheimer’s disease EEG changes would be non-invasive and cheap screening tools and could also help to predict future progression to clinical Alzheimer’s disease. However, the impact of amyloid-β deposition and neurodegeneration on EEG biomarkers needs to be elucidated. We included participants from the INSIGHT-preAD cohort, which is an ongoing single-centre multimodal observational study that was designed to identify risk factors and markers of progression to clinical Alzheimer’s disease in 318 cognitively normal individuals aged 70–85 years with a subjective memory complaint. We divided the subjects into four groups, according to their amyloid status (based on 18F-florbetapir PET) and neurodegeneration status (evidenced by 18F-fluorodeoxyglucose PET brain metabolism in Alzheimer’s disease signature regions). The first group was amyloid-positive and neurodegeneration-positive, which corresponds to stage 2 of preclinical Alzheimer’s disease. The second group was amyloid-positive and neurodegeneration-negative, which corresponds to stage 1 of preclinical Alzheimer’s disease. The third group was amyloid-negative and neurodegeneration-positive, which corresponds to ‘suspected non-Alzheimer’s pathophysiology’. The last group was the control group, defined by amyloid-negative and neurodegeneration-negative subjects. We analysed 314 baseline 256-channel high-density eyes closed 1-min resting state EEG recordings. EEG biomarkers included spectral measures, algorithmic complexity and functional connectivity assessed with a novel information-theoretic measure, weighted symbolic mutual information. The most prominent effects of neurodegeneration on EEG metrics were localized in frontocentral regions with an increase in high frequency oscillations (higher beta and gamma power) and a decrease in low frequency oscillations (lower delta power), higher spectral entropy, higher complexity and increased functional connectivity measured by weighted symbolic mutual information in theta band. Neurodegeneration was associated with a widespread increase of median spectral frequency. We found a non-linear relationship between amyloid burden and EEG metrics in neurodegeneration-positive subjects, either following a U-shape curve for delta power or an inverted U-shape curve for the other metrics, meaning that EEG patterns are modulated differently depending on the degree of amyloid burden. This finding suggests initial compensatory mechanisms that are overwhelmed for the highest amyloid load. Together, these results indicate that EEG metrics are useful biomarkers for the preclinical stage of Alzheimer’s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537 · cited 5×
“At the preclinical stage subjects are cognitively unimpaired but show evidence of cortical amyloid-β (Aβ) deposition which is considered to be the most upstream process in the pathological cascade of AD (Jack et al. , 2013) and is measured by amyloid PET or decreased amyloid-β 1-42 and amyloid-β 1-42 / amyloid-β 1-40…”
InfluentialSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
SMITH, S., & NICHOLS, T. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2008.03.061 · Cited by 5,250
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 1×
“The pathophysiological process of Alzheimer’s disease begins many years before the onset of symptoms (Bateman et al., 2012; Villemagne et al., 2013).”
MEG and EEG data analysis with MNE-Python
Gramfort, A. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00267 · Cited by 3,784
Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050
Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks
Palop, J. J., & Mucke, L. (2010) · Nature Neuroscience · doi:10.1038/nn.2583 · Cited by 1,651 · cited 2×
“Previous work in animal models has shown that intermediate levels of Aβ enhance synaptic activity presynaptically (Abramov et al. , 2009), whereas abnormally high levels of Aβ impair synaptic activity by inducing post-synaptic depression (Palop and Mucke, 2010).”
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
Gómez‐Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., Parisi, J. E., & Hyman, B. T. (1997) · Annals of Neurology · doi:10.1002/ana.410410106 · Cited by 1,489 · cited 1×
“However, it has been shown that there is a strong correlation between 18F-FDG PET hypometabolism in Alzheimer’s disease-signature regions and tau pathology, and also between hippocampal atrophy and tau pathology (Gómez-Isla et al., 1997; Nelson et al., 2012).”
Background
Cited by
The inter-relationship between delirium and dementia: the importance of delirium prevention
Fong, T. G., & Inouye, S. K. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00698-7 · Cited by 404
Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease
Wang, X., Huang, W., Su, L., Xing, Y., Jessen, F., Sun, Y., Shu, N., & Han, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00395-3 · Cited by 265
Biomarkers of neurodegeneration across the Global South
McGlinchey, E., Duran-Aniotz, C., Akinyemi, R., Arshad, F., Zimmer, E. R., Cho, H., Adewale, B. A., & Ibanez, A. (2024) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(24)00132-6 · Cited by 32
Structural inequality and temporal brain dynamics across diverse samples
Baez, S., Hernandez, H., Moguilner, S., Cuadros, J., Santamaria‐Garcia, H., Medel, V., Migeot, J., Cruzat, J., Valdes‐Sosa, P. A., Lopera, F., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.70032 · Cited by 21
Metadata
- Authors
- Gaubert, S., Raimondo, F., Houot, M., Corsi, M.-C., Naccache, L., Diego Sitt, J., Hermann, B., Oudiette, D., Gagliardi, G., Habert, M.-O., Dubois, B., De Vico Fallani, F., Bakardjian, H., Epelbaum, S., & Initiative, A. D. N.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-06-18
- Volume
- 142
- Issue
- 7
- Pages
- 2096-2112
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2952277065
- Cited by
- 235
- References
- 71
- FWCI
- 15.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.